Bogie; Terence J. - US Patent Attorneys and Agents

Attorney: Bogie; Terence J.

Number of patents: 67
Last date: May 15, 2012

Browse patents
Browse applications

Number	Title	Issue Date
8178561	Method for modulating GPR119 G protein-coupled receptor and selected compounds A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therape...	05/15/2012
8158648	Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrog...	04/17/2012
8148396	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrog...	04/03/2012
8143425	Heterocyclic aromatic compounds useful as growth hormone secretagogues Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I wherein R1, R1a	03/27/2012
8119658	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrog...	02/21/2012
8093257	[6,5]-bicyclic GPR119 G protein-coupled receptor agonists Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy...	01/10/2012
8076322	[6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy...	12/13/2011
8003796	Pyridone GPR119 G protein-coupled receptor agonists Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy...	08/23/2011
7928230	Method for modulating GPR119 G protein-coupled receptor and selected compounds A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therape...	04/19/2011
7910583	[6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy...	03/22/2011
7888376	Heterocyclic CETP inhibitors Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein. ...	02/15/2011
7863333	N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.	01/04/2011
7834178	Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrog...	11/16/2010
7829571	Cyclic derivatives as modulators of chemokine receptor activity The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma. ...	11/09/2010
7812024	Modulators of serotonin receptors The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metab...	10/12/2010
7795436	Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at...	09/14/2010
7790770	Heterocyclic CETP inhibitors Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein. ...	09/07/2010
7790745	Tetrahydroisoquinoline LXR Modulators A compound of formula I wherein X, R1, R2a, R3a, R3b, R4a, R4b, R4c and R5 are defined herein. ...	09/07/2010
7776884	Cyclic derivatives as modulators of chemokine receptors activity The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis, asthma, restin...	08/17/2010
7772232	Quinazolinyl compounds as inhibitors of potassium channel function A compound of formula I wherein m, n, A, B, D, E, G, H, Y, R1, R2, R3, R4, R5, and R8, are described herein. Said compounds being useful as inhibitors of pot...	08/10/2010
7741317	LXR modulators A compound of formula I wherein A, X, q, R1, R2a, R2b, R2c, R3a, and R3b are defined herein. ...	06/22/2010
7727978	Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-Beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrog...	06/01/2010
7696205	Cyclic derivatives as modulators of chemokine receptor activity The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.	04/13/2010
7687508	Cyclic derivatives as modulators of chemokine receptor activity This invention relates generally to modulators of chemokine receptor activity having unexpected combination of desirable pharmacological properties. Pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and prevention...	03/30/2010
7671062	Modulators of chemokine receptor activity, crystalline forms and process The present invention provides a novel antagonist or partial agonists/antagonists of MCP-1 receptor activity: N-((1R,2S,5R)-5-(isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide,	03/02/2010
7652023	Heterocyclic CETP inhibitors Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein. ...	01/26/2010
7629351	N-((1R,2S,5R)-5-(-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process The present invention provides a novel antagonist or partial agonists/antagonist of MCP-1 receptor activity: N-((1R,2S,5R)-5-tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide,	12/08/2009
7618980	Pyrrolo(oxo)quinolines as 5HT ligands The present application provides pyrrolo(oxo)isoquinolines as modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin recept...	11/17/2009
7615556	Piperazinyl derivatives as modulators of chemokine receptor activity The present application describes modulators of MIP-1α of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, T, W, R1, R4, R5, R5a and R5...	11/10/2009
7601844	Piperidinyl derivatives as modulators of chemokine receptor activity The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as wel...	10/13/2009
7584719	Apparatus and method for restraining a laboratory animal An animal restraint includes first and second upright plates. A plurality of bars, each having a first end mounted to the first plate and a second end mounted to the second plate, form an enclosure that is dimensioned to closely receive an animal. The plurality of b...	09/08/2009
7582654	Heterocyclo inhibitors of potassium channel function Novel heterocyclo compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activatin...	09/01/2009
7579360	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrog...	08/25/2009
7572807	Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrog...	08/11/2009
7572805	Pyrrolo(oxo)isoquinolines as 5HT ligands The present application describes compounds according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and...	08/11/2009
7569590	Use of thianecarboxamides as dgat inhibitors The present application describes methods of treating obesity using DGAT-1 inhibitors according to Formula I: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R	08/04/2009
7541362	Heterocyclic dihydropyrimidine compounds Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultr...	06/02/2009
7507730	Substituted pyrazolo[1,5-a]pyrimidines as potassium channel activators Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultr...	03/24/2009
7482335	Cyclic derivatives as modulators of chemokine receptor activity The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma. ...	01/27/2009
7479496	Substituted spiro azabicyclics as modulators of chemokine receptor activity The present application describes modulators of CCR3 of formula (Ia) and (Ib): or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5...	01/20/2009

«First «Previous1 2 Next»Last»

PatentStorm

Bizarre Patents

PatentStorm News

Attorney: Bogie; Terence J.